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Summary.-A series of consecutive unselected patients with primary breast car-
cinoma and their age-matched controls were studied for serum CEA in relation to
clinical findings. Raised CEA was found in a similar frequency in patients with pri-
mary breast cancer (pre- and postoperative) and in the control women: 16%, 11%
and 110%, respectively, exceeded the selected upper limit of the reference range
(13 ng/ml) with a double-antibody radioimmunoassay. In the breast-cancer patients,
however, 48% of the raised CEA levels exceeded 16 ng/ml, compared with only 20%
in the controls. Significant correlations (r,0-3) were found between CEA levels and
tumour size, TNM classification and a combined clinical and histopathological
classification. A high frequency of raised CEA values in the advanced breast-cancer
patients was the essential contribution to these positive correlations. A correlation
coefficient of 0-6 was found between pre- and postoperative CEA values. The fre-
quency of smoking and/or chronic disease was unexpectedly high in patients as well
as in controls with high CEA.
RAISED levels of carcinoembryonic anti-
gen (CEA) can be demonstrated not only
in patients with malignant tumours (Gold
et al., 1973; Hansen et al., 1974) but also
in some patients with benign disease and
in healthy persons. In advanced breast
cancer raised levels of CEA are reported
at a frequency of about 70-80% (Chu &
Nemoto, 1973; Steward et al., 1974; Tor-
mey et al., 1975; Wang et al., 1975; Lamerz
& Ruider, 1976; Tormey et al., 1977). In
primary breast cancer raised CEA values
are reported in frequencies from 0%0 in
locally confined cancers (Lamerz &
Ruider, 1976) to 55%/ in a series of oper-
able but otherwise undefined cancers
(Borthwick et al., 1977). The differences
between the results of the various studies
probably depend on the composition of
the patient groups and also on the criteria
for CEA elevation. In some studies (Stew-
ard et al., 1974; Wahren et al., 1978) CEA
levels have been shown to correlate with
the stage of the disease according to a
clinical classification as with CEA in
colonic carcinoma (Zamcheck et al., 1975).
Pre-treatment and post-treatment CEA
levels have been studied in a few series of
primary breast cancer (Wang et al., 1975;
Tormey et al., 1977; Wahren et al., 1978).
In the study of Wang et al. (1975) a post-
operatively raised CEA level indicated
faster recurrence, whilst preoperative CEA
levels did not correlate with the recurrence
rates. In earlier studies, the patients (or
patient materials) were selected and the
advancedstageswereveryoftenover-repre-
sented. When controls were examined they
were usually not matched for age or sex.
The present investigation wasperformed
to obtain information on CEA levels in an
unselected population of consecutively
diagnosed primary breast cancers in
patients within a geographically defined
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area and their corresponding age-matched
controls without a history ofbreast cancer.
A short follow-up was also made on those
patients with elevated CEA values before
or after treatment.
SUBJECT AND METHODS
179 women with breast carcinoma and 179
age-matched non-hospitalized controls with-
out a history of breast cancer are included in
the study.
Patients.-The patients are a consecutive
series of women with breast cancer diagnosed
from October 1975 toMarch 1976 in4 Swedish
counties. The total number of patients was
181, but 2 of them refused treatment and
participation in the study. The age of the
patients ranged from 30 to 90 years with a
mean of 63 (Fig. 1). The patients were classi-
fied according to the TNM classification
(UICC, 1974) and also a combined clinical and
histopathological classification especially
taking into account the histological examina-
tion of the axillary nodes (Table I). The pre-
operative evaluation included clinical assess-
ment, haematological and biochemical labora-
tory tests andX-ray examination ofthe chest.
Patients with symptoms, pathological labora-
tory tests or advanced local disease were also
examined by liver and skeleton scans and
X-rays of the spine and pelvis. The surgical
treatment was a simple mastectomy with or
without lymphnode biopsy or a modified
nunmber
of women
TABLE I.-Staging according to the TNM
classification and the combined clinical
and hi8topathological classification
Combined clinico-
histopathological
TNM classification* classificationt
No. No.
Stage patients % Stage patients %
0 7 5
I 69 39 I 64 49
II 85 47 Ila 15 12 34
Ilb 28 22}J
III 17 10 III 8 6
IV 8 4 IV 8 6
179 100 130t 100
* UICC, Geneva, 1974.
tStage 0: preinvasive carcinoma.
I: no local tumour complications, no
axillary metastases;
hIa: no local tumour complications, proven
axillary metastases without periglandu-
lar growth or apical node involvement;
Ilb: no local tumour complications, proven
axillary metastases with periglandular
growth and/or apical node involvement.
III: locally advanced tumour in breast and/
or axilla.
I-III: no distant metastases known;
IV: distant metastases known.
t 49 women were operated without staging of the
axilla (simple mastectomy) and were thus un-
classifiable.
radical mastectomy. In stage IV patients a
simple mastectomy was performed for sani-
tary reasons.
The patients answered a questionnaire con-
cerning among other things, smoking habits
and earlier and current diseases. This infor-
mation was checked against the hospital
records. Blood samples (without additives)
for analysis of CEA in serum were drawn
before and after surgery. The first blood
sample was taken after admission to hospital
but before surgery and the second 10 days to
26 weeks after surgery, the median interval
being 3 weeks. Three quarters of the samples
were taken less than 6 weeks after surgery. In
the patient group, serum was available for
analysis ofCEA in 147 patientspreoperatively
and in 168 patients postoperatively. The dif-
ference from the total of 179 was due to a lack
of serum in some cases, and there was no
indication ofany systematic selection ofthese
patients.
Controls.-Each breast-cancer patient had
an age-matched control without a history of
breast cancer. The controls were selected from
30 40 50 60 70 80 90 age
FIG. 1.-Age distribution in 179 breast-
cancer patients.
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a computerized population register and the
age-matching was within the range of 3 days.
Twenty-five ofthe primarily selected controls
refused participation or were inaccessible and
had to be replaced by alternative controls.
This was done in a way to minimize the risk
ofaffecting the results, according to a method
described by Adami & Vegelius (1978).
All controls answered a questionnaire
identical to that for the patient group. In
addition, they were all clinically examined,
especially to exclude breast carcinoma, and
blood samples were drawn. Serum foranalysis
ofCEAwas available from 174controlwomen.
CEA radioimmunoassay.-The sera of pa-
tients and controls were directly sent to the
investigators, immediately frozen and stored
at -90W. A detailed comparison to the RIA
of Hoffman-La Roche was made twice
(Wahren et al., 1975; Zimmerman, 1978). The
normal value was slightly higher than in the
Roche test and comparable to that of other
double-antibody assays (Laurenceetal., 1972).
The results in evaluating raised CEA were
similar to that obtained with the Roche assay
(Wahren et al., 1975) and also to the original
RIA ofGold et al. (1973).
A double-antibody radioimmunoassay was
performed. 0-2 ml of a patient's serum or a
predetermined CEA amount was mixed with
0-1 ml of absorbed diluted rabbit anti-CEA
serum in phosphate-buffered saline (PBS)
with 1% bovine serum albumin (BSA) and
incubated for 6 h at 37°C. To a dilution of
antiserum precipitating 65% of maximum
precipitable labelled CEA, 0-1 ml of125J-CEA
was added. Labelling was performed by a
modified chloramine-T method (Hunter,
1971). The mixture was incubated overnight
at room temperature. Thereafter, 1 ml of
cellulose-bound sheep-anti-rabbit IgG diluted
1:50 (Organon, Oss, Holland) was added,
followed by incubation for 2 h at 37W with
intermittent agitation. The sedimentation of
antigen-antibody complexes was achieved by
low-spread centrifugation, 1000 g for 5 min.
After one wash in PBS the pellet was counted
and the percentage of 125I-CEA binding was
calculated. Perchloric acid (PCA) extraction
of the sera before assay made no difference
to the CEA values.
All the serum assays were performed in a
few consecutive assays to keep variation low
(Zimmerman, 1978). Theintra-assayvariation
was 5%, the inter-assay variation 10%.
The lowest detectable dose was 0-2 ng CEA.
Values exceeding 13 ng/ml (mean value of
normal persons +1 s.d.) were considered
abovenormal. Immunologicallycross-reacting
substances other than CEA may interfere in
bothassays, althoughNCA (non-specific cross-
reactive antigen) has to be present in Hg
amounts to cause inhibitionl (Gadler et al.,
1978). The intactness of serum proteins of
the stored sera was controlled by IgG and
IgM quantification with Tripartigen immu-
nodiffusion plates (Behringwerke, Marburg-
Lahn, Germany) and only sera with levels
above the lower normal limit were evaluated.
RESULTS
The distributions of CEA values in
breast-cancer patients before and after
surgery and in controls are presented in
Fig. 2. The means and s.d. were preopera-
No.
50
25-
°l) 7 9 11 13 15 17 19 21
Patients
preop.
CEA
27 ng/ml
No. Patients
50- postop.
25]
CEA
0 5 7 9
I
1 1 19 0 5 7 9 11 13 1517 1921 23 29 ngIml
No.
50-
25-
00
Controlc
7 9 11 13 15 17 19 21
CEA
ng/ml
FIG. 2.-Distribution of CEA values in pre-
operative and postoperative breast-cancer
patients and in controls.
tively 10-8A 3-2, postoperatively 10-1 4-5
ng/ml and in controls 10 5+2-3. There was
no significant difference between them
(P>0 05, t test). The CEA values exceeded
the selected upper limit of the reference
range (13 ng/ml) in 16% (23/147) pre-
operatively in 11% (18/168) postoperative-
ly and in 11% (20/174) of the controls. It
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TABLE II.-Distribution of CEA values in
relation to TNM 8tage
Preoper-
atively.
Stage
I
II
III
IV
Total
preop.
Postop-
eratively.
Stage
I
II
III
IV
Total
postop.
Controls
CEA ng/ml
<10
29
31
4
c)
10-13
25
27
5
13-16
2
4
4
c)
>16
4
6
0
No
value
9
17
4
c)
Total
69
85
17
Q
No. Patients preop.-
50- Controls
25]
ol ,_ CEA
-0 3i-1 -9 -7 -5 -3 -11 1 .3 .5 .7 .9 .11 ng/ml
I I h 1 = o No. Z Patients post
50- Controls
66 58 12 11 32 179 2
2 5 3 3 -13 -11 -9 -7 -5 -3 -) +1 +3 *5 +7 +9 +11
46
61
14
14
2
4
3
2
4
4
69
85
10 1 2 1 3 17 No.
2 2 0 4 0 8 50
119 31 8 10 11 179 251
96 58 16 4 5 179
top.-
CEA
ng/ml
Patients preop.-
Patients postop.
-13 -9 -7I5 -3 -)1 1I .37 +9
can also be seen in Table II that 48%
(11/23) of the patients with raised CEA
(>13 ng/ml) had avalue >16 ng/ml, while
the corresponding figure for the control
group was 20% (4/20).
The difference between the patient's
CEA value pre- and postoperatively and
in the corresponding age-matched control
woman was calculated. Fig. 3 shows the
distribution of these differences. The dif-
ferences between pre- and postoperative
values for each patient are also shown. All
histograms indicate essentially a normal
distribution with the mean difference near
to 0.
In the different TNM stages values >13
ng/ml were found preoperatively in 10%
in Stage I, 15% in Stage II, 31% in Stage
III and 50% in Stage IV. Postoperatively,
the corresponding frequencies were 8%,
7%, 21% and 50% respectively (Table II).
In all stages, except IV, the mean post-
treatment values were somewhat lower
than the pre-treatment levels. A raised
CEA occurred preoperatively as well as
postoperatively in 9 patients: 3 in Stage
IV, 2 in Stage III, 3 in Stage II and 1 in
Stage I. Fourteen patients with only pre-
operatively raised CEA values were classi-
fied according to the TNM classification
as Stage III in 1, Stage II in 8 and Stage
CEA
ng/ml
FIG. 3. Distribution of differences in CEA
values between breast cancer patients
preoperatively andpostoperatively (bottom
histogram) and between patients and their
corresponding controls.
I in 5. The postoperative value was
omitted in only one case (Stage II).
In Table III the mean CEA value is
shown for the different TNM stages, for
different tumour diameters according to
the T-classification of the TNM system,
and for the different groups according to
the clinico-histopathological classification.
Most mean values among the controls cor-
responding to the patients in the different
patient groups were between 10 and 11
ng/ml. In TNM stages I-III, T classifica-
tion TO-T3 and Stages 0-III ofthe clinico-
histopathological classification, the mean
values were all below 13 ng/ml. There was
a tendency to higher mean values in Stage
II and in T3 tumours. In Stage IV and in
T4 tumours the mean values of CEA were
all > 13 ng/ml and significantly higher
(P<0 05) than in Stages I-III and T1-T3,
respectively.
In Table IV some correlation coefficients
are shown. The highest found was that be-
tween the preoperative and postoperative
CEA values: 0-62 (P<0 001). Moderate
l- -4 U-
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TABLE III.-The mean value of CEA
according to TNM stage, T classification
and clinico-histopathological classification
Mean CEA (ng/ml)
A
TNM stage
I
II
III
IV
T classification
TO
TI
T2
T3
T4
Clinico-
histopath.
classification
0
I
IIa
lIb
III
IV
Pre-
operative
10-9 (60)t
10-9 (68)
11-5 (13)
13-3 (6)
10-2 (8)
10-8 (62)
11-0 (62)
11-8 (9)
14-5 (5)
8-8 (6)
9-8 (52)
10-6 (13)
11-2 (23)
11-2 (6)
13-3 (6)
Post-
operative
9-6 (65)
9-5 (81)
11-1 (14)
17-5 (8)
Controls*
10-7 (63)
10-3 (79)
10-5 (13)
10-4 (8)
9-2 (9) 10-6 (9)
9-6 (68) 10-6 (65)
9-7 (74) 10-4 (73)
11-7 (9) 9-6 (9)
18-.5 (6) II-.II (51
8-2 (7)
9-5 (58)
8-6 (15)
9-3 (28)
12-4 (7)
17-5 (8)
tion
Variable
Age
TNM stage
T classification
N classification
Clinico-histopath.
classification
Preop. CEA
Postop. CEA
CEA in controls
Preop.
r
0-06
0-18*
0-24t
0-03
0-321
0-62t
-0-03
TABLE V.-Clinical course after 18-24
months in 32 patients with raised CEA
values (>13 ny/ml)
Dead I
Clinical No Local Distant Dead from
stage recur- recur- meta with other e
(TNM) rence rence stases cancerdisease
I 7 0 1 0 2
II 9 0 1 2 1
III 3 1 1 0 0
IV 0 0 1 3 0
Total
number
of
patients
with
elevated
CEA
10
13
5
4
Total 19 1 4 5 3 32
iiovol \ number of recurrences or deaths do not
suggest that the high CEA values in most
cases predicted a prognosis worse than
11-8 (7) that expected from the clinical classifica-
10-6 (56) tion. It is notable, however, that all pa- 9-4 (15) tients withrecurrence ordeath from cancer 10-2 (28)
11-1 (6) (but also from other diseases) had CEA 10-4 (8) values exceeding 16 ng/ml.
Ading to the The occurrence of chronic or earlier
tions. malignant disease was, as well as smoking habits, related to CEA values. Of the 20
correlation women with raised CEA in the control
stoperative group,
8 were smokers, 6 had chronic
goe, TrN1M cardio-pulmonary disease and 13 had
sge Tnm chronic disease such as rheumatic disease,
cland com- liver disease or chronic pancreatitis. Only classifica- 4 were non-smokers and had no known
chronic disease. Of 32 patients with raised Postop. CEA value pre- and/or postoperatively, 6
0-16* were smokers, 2 had other malignant
0-28t disease, 11 cardio-pulmonary disease and
0-27t 16 other chronic disease. Only 8 were non- 0-10 smokers with no known complicating
0-37t disease.
0-62t
-0-06
*P < 0-05, tP < 0-01 and tP<0-001.
but highly significant correlations were
also found between CEA and T classifica-
tion and the clinico-histopathological
classification.
In Table V the follow-up results after
18-24 months are presented for all patients
with raised CEA values before and/or after
primary treatment. In Stages I-III the
DISCUSSION
In comparison with series of other
authors, the frequencies of raised pre- and
postoperative CEA values were low (16
and 11%, respectively). The frequency of
raised CEA values in the control group was
similar to that ofthe postoperative group,
and not significantly different from that in
the preoperative group. In other investiga-
tions, liver cirrhosis, ulcer disease, colitis,
diverticulitis, pancreatitis and several
* Controls are the women correspor
individual patients.
t In brackets, the number of observa
TABLE IV.-Product-moment
coefficients (r) for pre- and po
CEA values in relation to a
stage, tumour size, nodal statuw
bined clinico-histopathological
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other non-malignant but grave diseases
are reported to give raised CEA values in
30-60% ofthe patients (Martin etal., 1976;
Onizawa et al., 1976). Smoking is also re-
ported to give raised values of CEA to a
frequency of about 20% in the absence of
malignant disease (Hansen et al., 1974). In
control groups of other investigators,
raised CEA values are reported in fre-
quencies from 0% (Laurence et al., 1972)
to 42% (Onizawa et al., 1976). In our con-
trol group the raised values could be
explained by smoking or chronic disease
in all but 4 cases. In the patient group,
24/32 women with elevated CEA were
smokers or had severe non-malignant
diseases. In these cases it is impossible to
decide whether the raised CEA level is un-
specific or due to the malignant disease.
The most interesting finding in the
present study was that about the same
frequency of breast cancer patients and
age-matched controls had raised CEA
values, although values above 16 ng/ml
were more frequent in the patient group.
Wang et al. (1975) found a similar fre-
quency of raised CEA values in normal
women and in women with early breast
cancer pre- and postoperatively, but in
other investigations (Laurence et al., 1972;
Hansen et al., 1974; Onizawa et al., 1976;
Borthwick et al., 1977) the controls had a
lower frequency of raised levels than the
breast-cancer patients. The disagreement
between previous investigations may not
only be due to different distributions with
respect to the stage ofthe disease but also
to a different composition of the control
groups. In our unselected series ofpatients
with breast cancer and in age-matched
controls it seems evident that factors other
than cancer are important for the level of
CEA. This statement is based on the high
frequency of smokers and sufferers from
chronic diseases known to give raised CEA
values. An exception is Stage IV cancer.
A high frequency of raised CEA values in
advanced breast cancerisverifiedinseveral
studies (e.g. Martin et al., 1976; Neville,
1976).
The significant correlations in the pre-
sent study between CEA and clinical
classification can mainly be explained by
the strong influence of a few high CEA
values in advanced carcinomas. The same
seems to be the case in studies by Steward
et al. (1974) and Wahren et al. (1978) but
not in the study of Lamerz & Ruider
(1976). The finding of raised CEA values
in carcinoma in an advanced stage is at
present of little direct clinical importance
for the treatment. It may become of in-
terest in assessing indications for adjuvant
therapy and in the study of the biology of
tumour-cell populations.
The relationship between pre- and post-
operative CEA levels has been studied
earlier, but without conclusive results.
Wang et al. (1975) reported that high post-
operative CEA levels often indicated early
recurrence, but this remains to be verified
in larger series. We found a correlation co-
efficient of about 0-6 between pre- and
postoperative values. In the present series
it is too early to evaluate any possible re-
lationship between raised pre- and post-
operative CEA values and the frequency
of and interval before recurrence. Of 5
patients classified as TNM stage I or II
and with elevated CEA levels, 3 suc-
cumbed from causes other than breast
cancer within 18-24 monthspostoperative-
ly (Table V). Further follow-up of the
patients as well as the controls may give
interesting information.
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